Theragenomic Medicine

Blog Archives

Stuff to read: Why should our Y chromosome disappear, after all?

Posted on January 19, 2019 by by

thassodotcom Posted in In The Press, Thasso Post, Theragenomic Medicine No Comments ↓

January 21, 2019 – Stuff to Read: As the Y chromosome is disappearing, we prepare ourselves to say goodbye to men, while asking if we could, and/or should, engineer animals to be as smart as us as humans?

As the person behind thasso.com and the writer of some of the posts to be found on thasso post,

…

Tags: ANI-MALES, Karyotype, Masculinity, Master Switch Gene, Perrault Syndrome, Sexual Differentiation, SRY Gene, Thasso Post, Theragenomic Medicine, Therians, Turner Syndrome, XX Genotype, XY Genotype, Y Chromosome

Combined hormonal contraception: Is there an unacceptable health risk?

Posted on January 15, 2019 by by

thassodotcom Posted in Genetic Predisposition, New Research, Thasso Post, Theragenomic Medicine No Comments ↓

January 15, 2019 – The World Health Organization (WHO) classifies combined hormonal contraception as an unacceptable health risk in the presence of a known thrombogenic mutation but advises against routine thrombophilia genetic testing before initiating combined oral contraceptives (COC’s) on the grounds of high screening costs and low prevalence.

…

Tags: Antithrombin Deficiency, Combined Oral Contraceptives (COCs), Factor V Leiden, Genetic Discrimination, Genetic Testing, Ischemic Stroke, Protein C Deficiency, Protein S Deficiency, Thasso Post, Theragenomic Medicine, Thrombogenic Mutation, Venous Thromboembolism (VTE), World Health Organization (WHO)

Sweet taste receptor gene TAS1R2 and chocolate powder

Posted on January 13, 2019 by by

thassodotcom Posted in Allelic Variant, Genetic Background, Genetic Predisposition, New Research, Thasso Post, Theragenomic Medicine No Comments ↓

January 13, 2019 – Are genetic variations in the sweet taste receptor gene related to chocolate powder and dietary fiber intake in obese children and adolescents? This was the question in a recent study just published in the Journal of Personalized Medicine. On one hand,

…

Tags: Childhood, Chocolate, Dietary Fiber Intake, Food Choice, Genetic Polymorphism, Obesity, Sweet Taste Receptor Gene TAS1R2, TAS1R2 Allelic Variants, TAS1R2 Gene, Taste, Thasso Post, Theragenomic Medicine

Migalastat (Galafold): New treatment for Fabry disease

Posted on January 12, 2019 by by

thassodotcom Posted in New Drug Approval, Rare Diseases, Thasso Post, Theragenomic Medicine No Comments ↓

January 12, 2018 – Fabry disease is an inherited disorder caused by mutations (alterations) in the alpha-galactosidase A (GLA) gene located on the X-chromosome. Fabry disease is rare and affects both males and females. It is estimated that classic Fabry disease (the most severe type) affects approximately one in 40,000 males.

…

Tags: Alpha-Galactosidase A Gene (GLA), Fabry disease, Globotriaosylceramide (GL-3), Migalastat (Galafold), Rare Disease, Thasso Post, Theragenomic Medicine

Is there breast implant-associated cancer (BIA-ALCL)?

Posted on January 9, 2019 by by

thassodotcom Posted in In The Press, New Safety Information, Rare Diseases, Regulatory Announcement, Thasso Post, Theragenomic Medicine 1 Comment ↓

January 09, 2019 – Women should be alerted: Is there a thing like breast implant associated cancer (BIA-ALCL)? Yes, there is. Not every woman with a breast implant will get it, however. In fact, BIA-ALCL seems to be a rather rare condition; unfortunately,

…

Tags: Breast Implant Associated Cancer (BIA-ALCL), L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), Rare Disease, Thasso Post, Theragenomic Medicine

You cannot hide it: Your face tells all about your ID

Posted on January 8, 2019 by by

thassodotcom Posted in Allelic Variant, Genetic Background, Genetic Predisposition, New Research, Rare Diseases, Thasso Post, Theragenomic Medicine No Comments ↓

January 08, 2019 – The interpretation of genetic variants after genome-wide analysis is complex in a selection of heterogeneous disorders which are at the base of a condition termed intellectual disability (ID). Generally, the cause of intellectual disability (ID) is unknown in about one-

third to one-half of cases.

…

Tags: Deep Phenotyping, Face2Gene, Facial Gestalt, Intellectual Disability (ID), Koolen-de-Vries Syndrome, PACS1 Gene, PHIP Gene, PPM1D Gene, Rare Genetic Disease, Selfie, Thasso Post, Theragenomic Medicine

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Tagraxofusp-erzs (Elzonris) FDA approved

Posted on December 30, 2018 by by

thassodotcom Posted in New Drug Approval, Rare Diseases, Thasso Post, Theragenomic Medicine No Comments ↓

December 30, 2018 – Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, including the lymph nodes and the skin and often presents as or evolves into acute leukemia. The disease is more common in men than women and in patients 60 years and older.

…

Tags: American Food & Drug Administration (FDA), Black Boxed Warning, Blastic Plasmacytoid Dendritic Cell Neoplasm, Capillary Leak Syndrome, Interleukin-3 Receptor (CD123), Life-threatening Adverse Effect, Rare Disease, Tagraxofusp-erzs (Elzonris), Thasso Post, Theragenomic Medicine

Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk

Posted on December 20, 2018 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

…

Tags: Britisch Medical Journal (BMJ), Cholangiocarcinoma, Diabetes, Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, DPP-4 Inhibitor Class of Drugs, DPP4 Gene, GLP-1 Receptor Agonist, GLP1R Gene, Glucagon-Like Peptide-1 (GLP-1) Receptor, Glyxambi (Empagliflozin / Linagliptin), Janumet (Sitagliptin / Metformin), Januvia (Sitagliptin), Jentadueto (Linagliptin / Metformin), Kazano (Alogliptin / Metformin), Kombiglyze XR (Saxagliptin / Metformin), Nesina (Alogliptin), Onglyza (Saxagliptin), Oseni (Alogliptin / Pioglitazone), Qtern (Dapagliflozin / Saxagliptin), Thasso Post, Theragenomic Medicine, Tradjenta (Linagliptin)

CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy: Prime time already?

Posted on December 12, 2018 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Allelic Variant, Children, Clinical Development, Congenital, Gene Therapy, Genetic Predisposition, In The Press, Personalized Medicine, Rare Diseases, Thasso Post, Theragenomic Medicine No Comments ↓

December 12, 2018 – The application of CRISPR/Cas9 based molecular technology in the field of gene editing (or genome editing) has recently had its exploded limelight exposure for a couple of reasons. The question arises if this exposure is earned or somewhat premature.

…

Tags: CCR 5 Gene, CRISPR-Cas9, Duchenne Muscular Dystrophy, Dystrophin Gene (DMD), Embryonal Gene Editing, Exxon Skipping Therapy, Fatal X-linked recessive Neuromuscular Disease, Gene Editing, Genetically Edited Babies, Hypertrophic Cardiomyopathy (HCM), Immune Response Activation, MYBCP3 Gene, Off-Targeting, Sub-Optimal In Vivo Delivery, Thasso Post, Theragenomic Medicine, Translation Into The Clinic

First ever treatment for Lambert-Eaton myasthenic syndrome (LEMS) FDA approved

Posted on December 4, 2018 by by

thassodotcom Posted in New Drug Approval, Rare Diseases, Regulatory Announcement, Thasso Post, Theragenomic Medicine 1 Comment ↓

December 04, 2018 – The American Food and Drug Administration (FDA) has just approved its first ever treatment, Amifampridine (Firdapse), for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder for adult patients. LEMS affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients.

…